Association between FIB-4 and Non-HDL Cholesterol in Occupational Health Examinations

Document Type : 6th congress of endocrinology & metabolism

Authors

1 Clinical Research Development Center, Najafabad Branch, Islamic Azad University, Najafabad, Iran

2 Nosocomial Infection Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

3 Department of E-learning in Medical Education, Center of Excellence for E-learning in Medical Education, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

4 Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

5 Department of Community and Family medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

10.48305/jims.v43.i827.0969

Abstract

Background: Non-alcoholic fatty liver disease (NAFLD) is a growing global health burden, strongly linked to metabolic disorders and cardiovascular disease (CVD). While the Fibrosis-4 (FIB-4) index is a validated non-invasive tool for assessing liver fibrosis risk, its relationship with lipid profiles, particularly non-high-density lipoprotein cholesterol (non-HDL-C), remains understudied. This research aimed to evaluate the prevalence of NAFLD-related fibrosis risk and its association with non-HDL-C among working-age adults in Iran, emphasizing implications for early metabolic and cardiovascular risk stratification.
Methods: A cross-sectional study analyzed 4,817 employed individuals (aged 35–65 years) undergoing routine occupational health exams in Isfahan, Iran (2023–2024). Participants with viral hepatitis or inherited liver diseases were excluded. FIB-4 scores were calculated using age, AST, ALT, and platelet counts, categorizing fibrosis risk as low (≤1.30), moderate (1.30–2.67), or high (>2.67). Non-HDL-C was derived from total cholesterol minus HDL-C, stratified into five clinical categories.
Findings: The study population was mainly male (91%), with a mean BMI of 26.5 kg/m². Most participants exhibited low FIB-4-derived fibrosis risk (92.3%), while 7.5% and 0.2% had moderate and high risk, respectively. Non-HDL-C levels showed a weak inverse correlation with FIB-4 scores (r = -0.091, p < 0.001), with higher non-HDL-C categories linked to reduced fibrosis risk (p = 0.007). For instance, 46.5% of moderate/high-risk individuals had non-HDL-C <130 mg/dL versus 36.5% in the low-risk group. Age and male sex were independently associated with elevated fibrosis risk (p < 0.001). Despite statistical significance, the clinical significance of the inverse lipid-fibrosis relationship is still unclear and requires further investigation of the mechanisms.
Conclusion: The result of present study highlights the utility of FIB-4 as a non-invasive tool for identifying NAFLD-related fibrosis risk in occupational populations. The paradoxical inverse association between non-HDL-C and fibrosis stages underscores the complexity of lipid metabolism in NAFLD pathogenesis. Integrating FIB-4 and lipid profiling may improve early detection of metabolic and cardiovascular complications.

Highlights

Shakiba Seifi:  Google Scholar, PubMed

Keywords

Main Subjects


  1. Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut. 2020; 69(9): 1691-705.
  2. Kjaergaard M, Lindvig KP, Thorhauge KH, Andersen P, Hansen JK, Kastrup N, et al. Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease. J Hepatol 2023; 79(2): 277-86.
  3. Lee J, Vali Y, Boursier J, Spijker R, Anstee QM, Bossuyt PM, Zafarmand MH. Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: A systematic review. Liver Int 2021; 41(2): 261-70.
  4. Xuan Y, Zhu M, Xu L, Huangfu S, Li T, Liu C, et al. Elevated non-HDL-C to HDL-C ratio as a marker for NAFLD and liver fibrosis risk: a cross-sectional analysis. Front Endocrinol (Lausanne) 2024; 15: 1457589.

Katsiki N, Mikhailidis DP, Mantzoros CS. Non-alcoholic fatty liver disease and dyslipidemia: An update. Metabolism 2016; 65(8): 1109-23. 

Volume 43, Issue 827
3rd Week,, October: 6th International and 8th Iranian Congress of Endocrinology & Metabolism Updates
September and October 2025
Pages 969-971
  • Receive Date: 11 June 2025
  • Accept Date: 30 July 2025